Media coverage about Aptevo Therapeutics (NASDAQ:APVO) has trended somewhat negative recently, according to Accern. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aptevo Therapeutics earned a coverage optimism score of -0.06 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.0763687373121 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
NASDAQ APVO traded up $0.03 on Monday, hitting $3.20. The company had a trading volume of 35,297 shares, compared to its average volume of 173,346. The firm has a market cap of $66.93, a PE ratio of -2.09 and a beta of 0.67. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.08 and a current ratio of 5.14. Aptevo Therapeutics has a 12-month low of $1.15 and a 12-month high of $4.85.
In related news, insider Marvin L. White sold 100,000 shares of the business’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $2.93, for a total value of $293,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 15.60% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: “Aptevo Therapeutics (APVO) Getting Somewhat Negative News Coverage, Report Finds” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/09/aptevo-therapeutics-apvo-getting-somewhat-negative-news-coverage-report-finds.html.
About Aptevo Therapeutics
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.